{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:05:58Z","timestamp":1783717558846,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Oncology Nursing"],"published-print":{"date-parts":[[2004]]},"DOI":"10.1016\/j.ejon.2004.06.007","type":"journal-article","created":{"date-parts":[[2004,9,3]],"date-time":"2004-09-03T03:54:10Z","timestamp":1094183650000},"page":"S31-S40","source":"Crossref","is-referenced-by-count":105,"special_numbering":"S1","title":["Management of hand-foot syndrome in patients treated with capecitabine (Xeloda\u00ae)"],"prefix":"10.1016","volume":"8","author":[{"given":"Yvonne","family":"Lassere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejon.2004.06.007_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1081\/CNV-120000360","article-title":"Incidence and severity of HFS in colorectal cancer patients treated with capecitabine","volume":"20","author":"Abushullaih","year":"2002","journal-title":"Cancer Investigation"},{"key":"10.1016\/j.ejon.2004.06.007_bib2","first-page":"89","article-title":"Capecitabine plus gemcitabine is an active combination for patients with metastatic breast cancer refractory to anthracyclines and taxanes","volume":"22","author":"Andres","year":"2003","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.007_bib3","first-page":"257","article-title":"Phase III trial of infusional 5-fluorouracil\/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC)","volume":"23","author":"Arkenau","year":"2004","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.ejon.2004.06.007_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1600-0560.1999.tb01846.x","article-title":"Expression and localization of thymidine phosphorylase\/platelet-derived endothelial cell growth factor in skin and cutaneous tumors","volume":"26","author":"Asgari","year":"1999","journal-title":"Journal of Cutaneous Pathology"},{"issue":"3","key":"10.1016\/j.ejon.2004.06.007_bib5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0190-9622(91)70073-B","article-title":"Chemotherapy-induced acral erythema","volume":"24","author":"Baack","year":"1991","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1016\/j.ejon.2004.06.007_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/030089168807400315","article-title":"Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil","volume":"74","author":"Bellmunt","year":"1988","journal-title":"Tumori"},{"key":"10.1016\/j.ejon.2004.06.007_bib7","first-page":"102A","article-title":"Pyridoxine (B6) and amelioration of hand\/foot syndrome","volume":"9","author":"Beveridge","year":"1990","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.ejon.2004.06.007_bib8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.ejon.2004.06.007_bib9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0190-9622(08)80126-0","article-title":"Treatment of cytarabine acral erythema with corticosteroids","volume":"24","author":"Brown","year":"1991","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1016\/j.ejon.2004.06.007_bib10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7326\/0003-4819-97-1-61","article-title":"Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia","volume":"97","author":"Burgdorf","year":"1982","journal-title":"Annals of Internal Medicine"},{"issue":"Suppl. 4","key":"10.1016\/j.ejon.2004.06.007_bib11","first-page":"62","article-title":"Effective dose-modification scheme for the management of toxicities with capecitabine therapy","volume":"11","author":"Cassidy","year":"2000","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ejon.2004.06.007_bib12","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"First-line oral capecitabine therapy in metastatic colorectal cancer","volume":"13","author":"Cassidy","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ejon.2004.06.007_bib13","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","article-title":"XELOX (capecitabine plus oxaliplatin)","volume":"22","author":"Cassidy","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.007_bib14","unstructured":"Cassidy, J., Twelves, C., Nowacki, M.P., et al., 2004b. Improved safety of capecitabine versus bolus 5-fluorouracil\/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT phase III study). Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (abstract 219)."},{"key":"10.1016\/j.ejon.2004.06.007_bib15","article-title":"Use of \u201cbag balm\u201d as topical treatment of palmar-plantar erythrodysesthesia syndrome in patients receiving selected chemotherapeutic agents","volume":"20","author":"Chin","year":"2001","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.007_bib17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/sj.bjc.6601284","article-title":"Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer","volume":"89","author":"D\u2019Agostino","year":"2003","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.ejon.2004.06.007_bib51","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl. 7","key":"10.1016\/j.ejon.2004.06.007_bib18","first-page":"23","article-title":"Dihydropyrimidine dehydrogenase modulation in 5-FU pharmacology","volume":"12","author":"Diasio","year":"1998","journal-title":"Oncology"},{"issue":"9209","key":"10.1016\/j.ejon.2004.06.007_bib52","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejon.2004.06.007_bib19","first-page":"192","article-title":"Efficacit\u00e9 de la corticoth\u00e9rapie s\u00e9quentielle dans un cas d\u2019\u00e9ryth\u00e8me acral douloureux secondaire au 5-fluoro-uracile \u00e0 fortes doses","volume":"146","author":"Esteve","year":"1995","journal-title":"Annales de Medecine Interne (Paris)"},{"issue":"1","key":"10.1016\/j.ejon.2004.06.007_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00216925","article-title":"Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion","volume":"8","author":"Fabian","year":"1990","journal-title":"Investigational New Drugs"},{"issue":"2","key":"10.1016\/j.ejon.2004.06.007_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00002820-200304000-00011","article-title":"Current Canadian experience with capecitabine","volume":"26","author":"Gerbrecht","year":"2003","journal-title":"Cancer Nursing"},{"issue":"1","key":"10.1016\/j.ejon.2004.06.007_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/A:1015716617967","article-title":"Population pharmacokinetic analysis of the major metabolites of capecitabine","volume":"29","author":"Gieschke","year":"2002","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"3","key":"10.1016\/j.ejon.2004.06.007_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1046\/j.1365-2125.2003.01765.x","article-title":"Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients","volume":"55","author":"Gieschke","year":"2003","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"8","key":"10.1016\/j.ejon.2004.06.007_bib24","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO;2-H","article-title":"HFS associated with liposome-encapsulated doxorubicin therapy","volume":"75","author":"Gordon","year":"1995","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejon.2004.06.007_bib25","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/archderm.1996.03890290132023","article-title":"High-dose methotrexate-induced bullous variant of acral erythema","volume":"132","author":"Hellier","year":"1996","journal-title":"Archives of Dermatology"},{"issue":"5","key":"10.1016\/j.ejon.2004.06.007_bib26","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<965::AID-CNCR23>3.0.CO;2-Y","article-title":"HFS following prolonged infusion of high doses of vinorelbine","volume":"82","author":"Hoff","year":"1998","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ejon.2004.06.007_bib27","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0006-2952(97)00682-5","article-title":"Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts","volume":"55","author":"Ishikawa","year":"1998","journal-title":"Biochemical Pharmacology"},{"issue":"9","key":"10.1016\/j.ejon.2004.06.007_bib28","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1200\/JCO.1997.15.9.3164","article-title":"Diagnosis in oncology","volume":"15","author":"Jucgla","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.ejon.2004.06.007_bib29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1346-8138.1995.tb03354.x","article-title":"Three cases of chemotherapy-induced acral erythema","volume":"22","author":"Komamura","year":"1995","journal-title":"Journal of Dermatology"},{"issue":"3","key":"10.1016\/j.ejon.2004.06.007_bib30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00000637-198909000-00012","article-title":"Chemotherapy-induced acral erythema","volume":"23","author":"Kroll","year":"1989","journal-title":"Annals of Plastic Surgery"},{"key":"10.1016\/j.ejon.2004.06.007_bib31","volume":"20","author":"Lauman","year":"2001","journal-title":"Effect of pyridoxine on the incidence of palmar plantar erythroderma in patients receiving capecitabine, Proceedings of the American Society of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.ejon.2004.06.007_bib32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/1120009X.1994.11741178","article-title":"Dermatological toxicity from chemotherapy containing 5-fluorouracil","volume":"6","author":"Leo","year":"1994","journal-title":"Journal of Chemotherapy"},{"issue":"12 Suppl. 14","key":"10.1016\/j.ejon.2004.06.007_bib33","first-page":"31","article-title":"Effect of celecoxib on capecitabine-induced HFS and antitumor activity","volume":"16","author":"Lin","year":"2002","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.ejon.2004.06.007_bib34","doi-asserted-by":"crossref","first-page":"798","DOI":"10.7326\/0003-4819-101-6-798","article-title":"Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome","volume":"101","author":"Lokich","year":"1984","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1016\/j.ejon.2004.06.007_bib35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s002800050981","article-title":"Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia","volume":"44","author":"Lopez","year":"1999","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"11","key":"10.1016\/j.ejon.2004.06.007_bib36","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","article-title":"Toxicity of fluorouracil in patients with advanced colorectal cancer","volume":"16","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.ejon.2004.06.007_bib37","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1016\/j.ejon.2004.06.007_bib38","first-page":"753","article-title":"Capecitabine","volume":"26","author":"Mrozek-Orlowski","year":"1999","journal-title":"Oncology Nursing Forum"},{"issue":"4","key":"10.1016\/j.ejon.2004.06.007_bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","article-title":"Antineoplastic therapy-induced palmar plantar erythrodysesthesia (\u2018hand-foot\u2019) syndrome","volume":"1","author":"Nagore","year":"2000","journal-title":"American Journal of Clinical Dermatology"},{"issue":"4","key":"10.1016\/j.ejon.2004.06.007_bib40","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0305-7372(94)90017-5","article-title":"Infusional 5-fluorouracil in breast cancer","volume":"20","author":"Ng","year":"1994","journal-title":"Cancer Treatment Reviews"},{"issue":"12","key":"10.1016\/j.ejon.2004.06.007_bib41","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer","volume":"20","author":"O\u2019Shaughnessy","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.ejon.2004.06.007_bib42","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdg446","article-title":"High incidence of severe HFS during capecitabine-docetaxel combination chemotherapy","volume":"14","author":"Park","year":"2003","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ejon.2004.06.007_bib43","first-page":"271","article-title":"Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC)","volume":"23","author":"Patt","year":"2004","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.ejon.2004.06.007_bib44","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdg500","article-title":"Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer","volume":"14","author":"Scheithauer","year":"2003","journal-title":"Annals of Oncology"},{"issue":"Suppl. 1","key":"10.1016\/j.ejon.2004.06.007_bib53","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ejon.2004.06.005","article-title":"Development of and Clinical experience with capecitabine (Xeloda\u00ae) in the treatment of solid tumours","volume":"8","author":"Sternberg","year":"2004","journal-title":"European Journal of Oncology Nursing"},{"key":"10.1016\/j.ejon.2004.06.007_bib45","first-page":"82A","article-title":"Prevention of palmar-plantar erythrodysesthesia associated with liposome-encapsulated doxorubicin by oral dexamethasone","volume":"16","author":"Titgan","year":"1997","journal-title":"Proceeding of the American Society of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.ejon.2004.06.007_bib46","first-page":"1567","article-title":"Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes","volume":"4","author":"Vail","year":"1998","journal-title":"Clincal Cancer Research"},{"issue":"4","key":"10.1016\/j.ejon.2004.06.007_bib47","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1046\/j.1365-2133.1998.02487.x","article-title":"Acral erythema induced by chemotherapy with cisplatin","volume":"139","author":"Vakalis","year":"1998","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.ejon.2004.06.007_bib48","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO.2000.18.6.1337","article-title":"Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer","volume":"18","author":"Van Cutsem","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.ejon.2004.06.007_bib49","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-111-8-688","article-title":"Pyridoxine therapy for palmar-plantar erythrodysesthesia syndrome","volume":"111","author":"Vukelja","year":"1989","journal-title":"Annals of Internal Medicine"},{"issue":"17","key":"10.1016\/j.ejon.2004.06.007_bib50","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/85.17.1432","article-title":"Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with Taxotere","volume":"85","author":"Vukelja","year":"1993","journal-title":"Journal of the National Cancer Institute"}],"container-title":["European Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388904000547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388904000547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T04:24:47Z","timestamp":1549254287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1462388904000547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":52,"alternative-id":["S1462388904000547"],"URL":"https:\/\/doi.org\/10.1016\/j.ejon.2004.06.007","relation":{},"ISSN":["1462-3889"],"issn-type":[{"value":"1462-3889","type":"print"}],"subject":[],"published":{"date-parts":[[2004]]}}}